Teva to take $13m spanner from works to close $6.8bn Cephalon deal
This article was originally published in Scrip
Executive Summary
A minor divestment and the deal is done: Teva Pharmaceutical Industries has closed its $6.8 billion acquisition of Cephalon following the European Commission's approval of the deal conditional on Cephalon divesting a pipeline generic version of modafinil.